Work

Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications

Year: 2004

Type: review

Abstract: AIMS: In this retrospective analysis, we assessed the short-term risk of treatment-emergent diabetes (TED) among patients with schizophrenia during clinical trials of antipsychotic medications. METHOD: From a non-diabetic cohort of patients with schizophrenia (n=5013), the relationship between baseline non-fasting glucose measurement, presence at baseline of risk factors for diabetes, weight gain and therapy assignment on the risk of treatment-emergent diabetes were assessed. RESULTS: At the baseline assessment, about a third of patients identified with TED during treatment had non-fasting glucose levels over 7.8 mmol/l and two-thirds had multiple diabetes risk factors. Both baseline non-fasting glucose level and the presence of multiple pre-existing diabetes risk factors appeared to have a major impact on the risk of developing diabetes. CONCLUSIONS: Overall, risk factors for diabetes in patients with schizophrenia overlap those in the general population. The results also suggest that many patients identified with TED might have had pre-existing glycaemic abnormalities or a high baseline burden of diabetes risk factors.

Source: The British Journal of Psychiatry

DOI: 10.1192/bjp.184.47.s94

Authors: Patrizia Cavazzoni, Nitai Mukhopadhyay, Christopher Carlson, Alan Breier, John Buse

Institutions: Eli Lilly (United States), University of North Carolina at Chapel Hill

Language: English

Topic: Schizophrenia research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: American Diabetes Association, Eli Lilly and Company, Pfizer, School of Medicine, University of North Carolina at Chapel Hill